Literature DB >> 8328511

Nephrotic edema--pathogenesis and treatment.

B F Palmer1.   

Abstract

The cardinal features of the nephrotic syndrome are albuminuria, hypoalbuminemia, and edema. Traditionally, albuminuria was thought to be responsible primarily for the development of hypoalbuminemia. A decreased plasma-albumin concentration accompanied by a decreased plasma-oncotic pressure was thought responsible for the development of edema and secondary salt retention by the kidney. However, new findings have prompted a reevaluation of these relationships. For example, increased renal catabolism and blunted hepatic synthesis appear to play major roles in the development of hypoalbuminemia. Evidence suggests that primary, rather than secondary, salt retention by the kidney and activation of mechanisms that limit fluid movement across the capillary wall participate in the pathogenesis of the nephrotic syndrome and related edema. The treatment of patients with the nephrotic syndrome should limit proteinuria. This can be accomplished by administering angiotensin-converting enzyme inhibitors, lowering the protein content of the diet, and cautiously using non-steroidal antiinflammatory agents.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328511     DOI: 10.1097/00000441-199307000-00013

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  2 in total

1.  Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites.

Authors:  D C Brater; N Chalasani; J C Gorski; J C Horlander; R Craven; H Hoen; J Maya
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

Review 2.  Fluid balance concepts in medicine: Principles and practice.

Authors:  Maria-Eleni Roumelioti; Robert H Glew; Zeid J Khitan; Helbert Rondon-Berrios; Christos P Argyropoulos; Deepak Malhotra; Dominic S Raj; Emmanuel I Agaba; Mark Rohrscheib; Glen H Murata; Joseph I Shapiro; Antonios H Tzamaloukas
Journal:  World J Nephrol       Date:  2018-01-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.